Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2713–2736 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Healthy Adult
Interventions: Niagen®; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Multiple Sclerosis
Interventions: 95% Pure ECGC capsules 200mg, Placebo Comparator:; Drug
Lead sponsor: Louisiana State University Health Sciences Center in New Orleans; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Wound; Knee
Interventions: STRATIFIX, VICRYL; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Healthy, Elderly
Interventions: Lactobacillus rhamnosus GG ATCC 53103 (LGG), Placebo; Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 65 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hair Thinning
Interventions: Nutrafol Supplement Capsules, Placebo Capsules; Dietary Supplement · Other
Lead sponsor: Ablon Skin Institute Research Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Manhattan Beach, California

Conditions: Osteoarthritis, Knee
Interventions: Fisetin, Losartan, Placebo - Losartan, Placebo Fisetin; Drug
Lead sponsor: Steadman Philippon Research Institute; Other
Eligibility: 40 Years to 85 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Vail, Colorado

Conditions: Chronic Kidney Disease (Stage 3-4), Chronic Kidney Disease Mineral and Bone Disorder
Interventions: Dietary Phosphorus Intake; Dietary Supplement
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Peanut Allergy
Interventions: Dupilumab, Placebo matching dupilumab, AR101; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 25
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 21 more

Conditions: Nasal Congestion
Interventions: Diphenhydramine 50 mg, Diphenhydramine 25 mg, Pseudoephedrine 120 mg; Drug
Lead sponsor: Johnson & Johnson Consumer and Personal Products Worldwide; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 1,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 12
States / cities: Austin, Texas • Dallas, Texas • Kerrville, Texas + 4 more

Conditions: Impulsivity, Alcohol Consumption
Interventions: Phospholean, Placebo; Dietary Supplement
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Medical Abortion, Pain
Interventions: Dronabinol 5mg Cap, Placebo; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years to 89 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Open Label Run In Esomeprazole, Double Blind Esomeprazole, Double Blind Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 1 Month to 11 Months
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 14
States / cities: Phoenix, Arizona • Atlanta, Georgia • Park Ridge, Illinois + 11 more

Conditions: Diabetic Nephropathy
Interventions: Nidufexor, Placebo, Standard of Care (SoC); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Miami Lakes, Florida • Albany, New York • Norman, Oklahoma + 2 more

Conditions: HIV-1 Infection
Interventions: ISL, LEN, B/F/TAF, ISL/LEN FDC; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 44
States / cities: Beverly Hills, California • Los Angeles, California • Newport Beach, California + 33 more

Conditions: Endometriosis
Interventions: 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule; Drug
Lead sponsor: Kissei Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 22
States / cities: Birmingham, Alabama • Dothan, Alabama • Chiefland, Florida + 19 more

Conditions: Osteoarthritis
Interventions: Meloxicam Test Capsules, Placebo Capsules; Drug
Lead sponsor: Iroko Pharmaceuticals, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 40
States / cities: Birmingham, Alabama • Carmichael, California • Pismo Beach, California + 31 more

Conditions: Noise-induced Hearing Loss
Interventions: EPI-743, Placebo; Drug
Lead sponsor: Edison Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Acute Pain
Interventions: Suzetrigine (SUZ), HB/APAP, Placebo (matched to SUZ), Placebo (matched to HB/APAP); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 12
States / cities: Sheffield, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 8 more

Conditions: Brain Injuries, Brain Injuries, Traumatic, Brain Injury, Chronic
Interventions: Tolcapone 200 MG, Placebo; Drug · Other
Lead sponsor: Sheppard Pratt Health System; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Towson, Maryland

Conditions: NSAID, Pain Management
Interventions: Acetaminophen, Ibuprofen; Drug
Lead sponsor: University of Washington; Other
Eligibility: 12 Years to 59 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Neoplasms
Interventions: Exemestane, Celecoxib + Exemestane; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Dovitinib, Sorafenib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 34
States / cities: Fayetteville, Arkansas • La Jolla, California • Los Angeles, California + 26 more

Conditions: Postherpetic Neuralgia
Interventions: ADL5747, Placebo, Pregabalin; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Total Knee Arthroplasty, Post-operative Pain Control
Interventions: Liposomal Bupivacaine Peri-articular Injection, Adductor canal block; Procedure
Lead sponsor: Good Samaritan Regional Medical Center, Oregon; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Corvallis, Oregon

Search by objective public record fields.

Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism

Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis

The Use of STRATAFIX Suture Device Compared to Standard-of-care for Deep Tissue Closure in Total Knee Arthroplasty

Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine

Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Peri-menopausal and Menopausal Women With Thinning Hair

Use of Senolytic and Anti-Fibrotic Agents to Improve the Beneficial Effect of Bone Marrow Stem Cells for Osteoarthritis

Phosphate Assessment in Chronic Kidney Disease Patients Study

Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

To Determine if Diphenhydramine Works for Nasal Congestion at Two Different Doses

The Gut-brain Axis in Food Reward and Alcohol Consumption

Cannabinoids for Pain Control During Medical Abortion

Phase 3/Safety & Efficacy of Esomeprazole in Infants

Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

Study of Meloxicam Capsules to Treat Osteoarthritis Pain

Protective Effects of EPI-743 on Noise-Induced Hearing Loss

Evaluation of Efficacy and Safety of Suzetrigine for Acute Pain After an Abdominoplasty

A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury

Pre-emptive Analgesics in Orthodontic Treatment

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia

Adductor Canal Block Versus Liposomal Bupivacaine in TKA